CA3075305A1 - Cxcr-2 inhibitors for treating disorders - Google Patents
Cxcr-2 inhibitors for treating disorders Download PDFInfo
- Publication number
- CA3075305A1 CA3075305A1 CA3075305A CA3075305A CA3075305A1 CA 3075305 A1 CA3075305 A1 CA 3075305A1 CA 3075305 A CA3075305 A CA 3075305A CA 3075305 A CA3075305 A CA 3075305A CA 3075305 A1 CA3075305 A1 CA 3075305A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- cancer
- disorder
- pharmaceutically acceptable
- colchicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003112 inhibitor Substances 0.000 title claims description 139
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims abstract description 364
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 270
- 229960001338 colchicine Drugs 0.000 claims abstract description 180
- 201000010099 disease Diseases 0.000 claims abstract description 157
- 238000000034 method Methods 0.000 claims abstract description 145
- 102000000589 Interleukin-1 Human genes 0.000 claims abstract description 77
- 108010002352 Interleukin-1 Proteins 0.000 claims abstract description 77
- 102000003896 Myeloperoxidases Human genes 0.000 claims abstract description 41
- 108090000235 Myeloperoxidases Proteins 0.000 claims abstract description 41
- 102000019034 Chemokines Human genes 0.000 claims abstract description 16
- 108010012236 Chemokines Proteins 0.000 claims abstract description 16
- UCCNQCNIPRKLRP-CJNGLKHVSA-N n-[6-[(2r,3s)-3,4-dihydroxybutan-2-yl]oxy-2-[(4-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]-3-methylazetidine-1-sulfonamide Chemical compound N=1C(SCC=2C=CC(F)=CC=2)=NC(O[C@H](C)[C@@H](O)CO)=CC=1NS(=O)(=O)N1CC(C)C1 UCCNQCNIPRKLRP-CJNGLKHVSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims description 153
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims description 140
- 101710082498 C-X-C chemokine receptor type 2 Proteins 0.000 claims description 140
- 208000035475 disorder Diseases 0.000 claims description 90
- 201000005569 Gout Diseases 0.000 claims description 84
- 206010028980 Neoplasm Diseases 0.000 claims description 84
- 230000001404 mediated effect Effects 0.000 claims description 77
- 210000000440 neutrophil Anatomy 0.000 claims description 57
- 239000008194 pharmaceutical composition Substances 0.000 claims description 44
- 238000002560 therapeutic procedure Methods 0.000 claims description 44
- 239000013078 crystal Substances 0.000 claims description 39
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 30
- 230000004054 inflammatory process Effects 0.000 claims description 30
- 206010061218 Inflammation Diseases 0.000 claims description 29
- 230000002757 inflammatory effect Effects 0.000 claims description 27
- 206010033645 Pancreatitis Diseases 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 206010063837 Reperfusion injury Diseases 0.000 claims description 21
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 21
- -1 microalbumin Proteins 0.000 claims description 21
- 208000017520 skin disease Diseases 0.000 claims description 21
- 201000001320 Atherosclerosis Diseases 0.000 claims description 18
- 201000004681 Psoriasis Diseases 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 17
- 206010047115 Vasculitis Diseases 0.000 claims description 15
- 208000014674 injury Diseases 0.000 claims description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims description 14
- 102000004890 Interleukin-8 Human genes 0.000 claims description 14
- 108090001007 Interleukin-8 Proteins 0.000 claims description 14
- 239000011885 synergistic combination Substances 0.000 claims description 13
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 12
- 206010040070 Septic Shock Diseases 0.000 claims description 12
- 206010025135 lupus erythematosus Diseases 0.000 claims description 12
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 11
- 201000008937 atopic dermatitis Diseases 0.000 claims description 11
- 208000014951 hematologic disease Diseases 0.000 claims description 11
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 10
- 206010003246 arthritis Diseases 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 9
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 9
- 208000038016 acute inflammation Diseases 0.000 claims description 9
- 230000006022 acute inflammation Effects 0.000 claims description 9
- 208000026935 allergic disease Diseases 0.000 claims description 9
- 239000000090 biomarker Substances 0.000 claims description 9
- 206010006451 bronchitis Diseases 0.000 claims description 9
- 230000003463 hyperproliferative effect Effects 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 9
- 230000008733 trauma Effects 0.000 claims description 9
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 230000003448 neutrophilic effect Effects 0.000 claims description 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 201000004624 Dermatitis Diseases 0.000 claims description 7
- 206010021143 Hypoxia Diseases 0.000 claims description 7
- 102000003814 Interleukin-10 Human genes 0.000 claims description 7
- 108090000174 Interleukin-10 Proteins 0.000 claims description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
- 208000006011 Stroke Diseases 0.000 claims description 7
- 206010000496 acne Diseases 0.000 claims description 7
- 230000033115 angiogenesis Effects 0.000 claims description 7
- 208000002557 hidradenitis Diseases 0.000 claims description 7
- 208000027866 inflammatory disease Diseases 0.000 claims description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 7
- 208000030507 AIDS Diseases 0.000 claims description 6
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims description 6
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 6
- 206010003571 Astrocytoma Diseases 0.000 claims description 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 6
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 6
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 6
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 6
- 208000015943 Coeliac disease Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 206010011224 Cough Diseases 0.000 claims description 6
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 6
- 206010014561 Emphysema Diseases 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
- 208000012309 Linear IgA disease Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 6
- 208000009525 Myocarditis Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 206010034277 Pemphigoid Diseases 0.000 claims description 6
- 206010048895 Pityriasis lichenoides et varioliformis acuta Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 206010037575 Pustular psoriasis Diseases 0.000 claims description 6
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 208000009956 adenocarcinoma Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 230000003143 atherosclerotic effect Effects 0.000 claims description 6
- 230000001363 autoimmune Effects 0.000 claims description 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 6
- 208000029407 autoimmune urticaria Diseases 0.000 claims description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 6
- 201000009267 bronchiectasis Diseases 0.000 claims description 6
- 208000007451 chronic bronchitis Diseases 0.000 claims description 6
- 208000024376 chronic urticaria Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 208000031225 myocardial ischemia Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
- 201000010914 pustulosis of palm and sole Diseases 0.000 claims description 6
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims description 6
- 210000004994 reproductive system Anatomy 0.000 claims description 6
- 210000002345 respiratory system Anatomy 0.000 claims description 6
- 230000036303 septic shock Effects 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 230000009885 systemic effect Effects 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 206010043778 thyroiditis Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- 208000019553 vascular disease Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000028185 Angioedema Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 241001303601 Rosacea Species 0.000 claims description 4
- 208000004631 alopecia areata Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 230000007954 hypoxia Effects 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 210000000653 nervous system Anatomy 0.000 claims description 4
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 4
- 201000004700 rosacea Diseases 0.000 claims description 4
- 210000004872 soft tissue Anatomy 0.000 claims description 4
- 230000005747 tumor angiogenesis Effects 0.000 claims description 4
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 claims description 3
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims description 3
- 206010048799 Acute generalised exanthematous pustulosis Diseases 0.000 claims description 3
- 231100000104 Acute generalised exanthematous pustulosis Toxicity 0.000 claims description 3
- 208000005441 Acute generalized exanthematous pustulosis Diseases 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 3
- 206010002065 Anaemia megaloblastic Diseases 0.000 claims description 3
- 206010061424 Anal cancer Diseases 0.000 claims description 3
- 201000003076 Angiosarcoma Diseases 0.000 claims description 3
- 208000001839 Antisynthetase syndrome Diseases 0.000 claims description 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims description 3
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 3
- 206010069002 Autoimmune pancreatitis Diseases 0.000 claims description 3
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006448 Bronchiolitis Diseases 0.000 claims description 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 3
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 3
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 3
- 102100032752 C-reactive protein Human genes 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 208000006029 Cardiomegaly Diseases 0.000 claims description 3
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 3
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 3
- 201000009047 Chordoma Diseases 0.000 claims description 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 3
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 3
- 206010009137 Chronic sinusitis Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 3
- 208000034656 Contusions Diseases 0.000 claims description 3
- 201000006306 Cor pulmonale Diseases 0.000 claims description 3
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010048768 Dermatosis Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000021866 Dressler syndrome Diseases 0.000 claims description 3
- 208000000059 Dyspnea Diseases 0.000 claims description 3
- 206010013975 Dyspnoeas Diseases 0.000 claims description 3
- 201000009051 Embryonal Carcinoma Diseases 0.000 claims description 3
- 206010014824 Endotoxic shock Diseases 0.000 claims description 3
- 206010014950 Eosinophilia Diseases 0.000 claims description 3
- 206010014967 Ependymoma Diseases 0.000 claims description 3
- 206010015216 Erythema marginatum Diseases 0.000 claims description 3
- 206010015226 Erythema nodosum Diseases 0.000 claims description 3
- 206010049466 Erythroblastosis Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 206010016228 Fasciitis Diseases 0.000 claims description 3
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 208000005232 Glossitis Diseases 0.000 claims description 3
- 102000005720 Glutathione transferase Human genes 0.000 claims description 3
- 108010070675 Glutathione transferase Proteins 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 206010056328 Hepatic ischaemia Diseases 0.000 claims description 3
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 3
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims description 3
- 208000000903 Herpes simplex encephalitis Diseases 0.000 claims description 3
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 claims description 3
- 206010020608 Hypercoagulation Diseases 0.000 claims description 3
- 206010058490 Hyperoxia Diseases 0.000 claims description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000015865 IgA pemphigus Diseases 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102000004889 Interleukin-6 Human genes 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 3
- 206010022680 Intestinal ischaemia Diseases 0.000 claims description 3
- 208000009388 Job Syndrome Diseases 0.000 claims description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
- 206010023358 Keratoderma blenorrhagica Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 3
- 206010024227 Lepromatous leprosy Diseases 0.000 claims description 3
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims description 3
- 206010024434 Lichen sclerosus Diseases 0.000 claims description 3
- 108010051335 Lipocalin-2 Proteins 0.000 claims description 3
- 102000013519 Lipocalin-2 Human genes 0.000 claims description 3
- 208000000185 Localized scleroderma Diseases 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010025537 Malignant anorectal neoplasms Diseases 0.000 claims description 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 208000000682 Megaloblastic Anemia Diseases 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 206010027982 Morphoea Diseases 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims description 3
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims description 3
- 206010051606 Necrotising colitis Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010058105 Neutrophilic dermatosis Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010029888 Obliterative bronchiolitis Diseases 0.000 claims description 3
- 206010061876 Obstruction Diseases 0.000 claims description 3
- 208000022873 Ocular disease Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010030216 Oesophagitis Diseases 0.000 claims description 3
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 3
- 108010081689 Osteopontin Proteins 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 3
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 3
- 206010033661 Pancytopenia Diseases 0.000 claims description 3
- 206010033963 Parathyroid tumour Diseases 0.000 claims description 3
- 206010061336 Pelvic neoplasm Diseases 0.000 claims description 3
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
- 206010034299 Penile cancer Diseases 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 3
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 3
- 208000007641 Pinealoma Diseases 0.000 claims description 3
- 208000000766 Pityriasis Lichenoides Diseases 0.000 claims description 3
- 208000007452 Plasmacytoma Diseases 0.000 claims description 3
- 208000008601 Polycythemia Diseases 0.000 claims description 3
- 206010060932 Postoperative adhesion Diseases 0.000 claims description 3
- 208000004347 Postpericardiotomy Syndrome Diseases 0.000 claims description 3
- 208000007541 Preleukemia Diseases 0.000 claims description 3
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims description 3
- 206010036590 Premature baby Diseases 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000004531 Renal Artery Obstruction Diseases 0.000 claims description 3
- 206010038378 Renal artery stenosis Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 206010063897 Renal ischaemia Diseases 0.000 claims description 3
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 208000000924 Right ventricular hypertrophy Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 201000010208 Seminoma Diseases 0.000 claims description 3
- 101710190759 Serum amyloid A protein Proteins 0.000 claims description 3
- 102100032277 Serum amyloid A-1 protein Human genes 0.000 claims description 3
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 claims description 3
- 206010040943 Skin Ulcer Diseases 0.000 claims description 3
- 208000010040 Sprains and Strains Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 3
- 206010042342 Subcorneal pustular dermatosis Diseases 0.000 claims description 3
- 201000004326 Sulfhemoglobinemia Diseases 0.000 claims description 3
- 206010042490 Sulphaemoglobinaemia Diseases 0.000 claims description 3
- 208000010265 Sweet syndrome Diseases 0.000 claims description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 206010046431 Urethral cancer Diseases 0.000 claims description 3
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000005969 Uveal melanoma Diseases 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 3
- 208000014926 Vesiculobullous Skin disease Diseases 0.000 claims description 3
- 208000014070 Vestibular schwannoma Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 206010047924 Wheezing Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 206010052428 Wound Diseases 0.000 claims description 3
- 230000005856 abnormality Effects 0.000 claims description 3
- 208000004064 acoustic neuroma Diseases 0.000 claims description 3
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 3
- 201000003229 acute pancreatitis Diseases 0.000 claims description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 3
- 230000010085 airway hyperresponsiveness Effects 0.000 claims description 3
- 208000002353 alcoholic hepatitis Diseases 0.000 claims description 3
- 230000000172 allergic effect Effects 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 206010002224 anaplastic astrocytoma Diseases 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 230000002491 angiogenic effect Effects 0.000 claims description 3
- 201000011165 anus cancer Diseases 0.000 claims description 3
- 208000007474 aortic aneurysm Diseases 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- 208000001974 autoimmune enteropathy Diseases 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 208000006424 autoimmune oophoritis Diseases 0.000 claims description 3
- 206010071572 autoimmune progesterone dermatitis Diseases 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 210000002469 basement membrane Anatomy 0.000 claims description 3
- 208000015294 blood coagulation disease Diseases 0.000 claims description 3
- 208000014759 blood platelet disease Diseases 0.000 claims description 3
- 208000016363 blood protein disease Diseases 0.000 claims description 3
- 201000003848 bronchiolitis obliterans Diseases 0.000 claims description 3
- 208000023367 bronchiolitis obliterans with obstructive pulmonary disease Diseases 0.000 claims description 3
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 3
- 208000025188 carcinoma of pharynx Diseases 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 3
- 208000010353 central nervous system vasculitis Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims description 3
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims description 3
- 208000028831 congenital heart disease Diseases 0.000 claims description 3
- 230000009519 contusion Effects 0.000 claims description 3
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 claims description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 3
- 208000030381 cutaneous melanoma Diseases 0.000 claims description 3
- 208000002445 cystadenocarcinoma Diseases 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 210000002249 digestive system Anatomy 0.000 claims description 3
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 claims description 3
- 208000000718 duodenal ulcer Diseases 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 208000000292 ehrlichiosis Diseases 0.000 claims description 3
- 206010014665 endocarditis Diseases 0.000 claims description 3
- 210000000750 endocrine system Anatomy 0.000 claims description 3
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims description 3
- 208000037828 epithelial carcinoma Diseases 0.000 claims description 3
- 208000012814 erosive pustular dermatosis of the scalp Diseases 0.000 claims description 3
- 201000004799 erythema elevatum diutinum Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000006881 esophagitis Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 208000001130 gallstones Diseases 0.000 claims description 3
- 208000023368 generalized pustular psoriasis Diseases 0.000 claims description 3
- 208000007565 gingivitis Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 210000003128 head Anatomy 0.000 claims description 3
- 201000010235 heart cancer Diseases 0.000 claims description 3
- 208000024348 heart neoplasm Diseases 0.000 claims description 3
- 208000018578 heart valve disease Diseases 0.000 claims description 3
- 201000002222 hemangioblastoma Diseases 0.000 claims description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 3
- 208000034737 hemoglobinopathy Diseases 0.000 claims description 3
- 208000031169 hemorrhagic disease Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims description 3
- 206010051040 hyper-IgE syndrome Diseases 0.000 claims description 3
- 230000000222 hyperoxic effect Effects 0.000 claims description 3
- 230000009610 hypersensitivity Effects 0.000 claims description 3
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 3
- 208000018875 hypoxemia Diseases 0.000 claims description 3
- 208000018337 inherited hemoglobinopathy Diseases 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 208000003849 large cell carcinoma Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 208000013104 leukocyte disease Diseases 0.000 claims description 3
- 201000011486 lichen planus Diseases 0.000 claims description 3
- 201000002818 limb ischemia Diseases 0.000 claims description 3
- 206010024627 liposarcoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 claims description 3
- 208000012804 lymphangiosarcoma Diseases 0.000 claims description 3
- 210000004324 lymphatic system Anatomy 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 3
- 210000001006 meconium Anatomy 0.000 claims description 3
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 3
- 231100001016 megaloblastic anemia Toxicity 0.000 claims description 3
- 206010027191 meningioma Diseases 0.000 claims description 3
- 208000005135 methemoglobinemia Diseases 0.000 claims description 3
- 208000008275 microscopic colitis Diseases 0.000 claims description 3
- 206010027599 migraine Diseases 0.000 claims description 3
- 210000000214 mouth Anatomy 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 201000005962 mycosis fungoides Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 208000001611 myxosarcoma Diseases 0.000 claims description 3
- 210000003739 neck Anatomy 0.000 claims description 3
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 3
- 208000037916 non-allergic rhinitis Diseases 0.000 claims description 3
- 201000005737 orchitis Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 208000004019 papillary adenocarcinoma Diseases 0.000 claims description 3
- 201000010198 papillary carcinoma Diseases 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 3
- 208000025487 periodic fever syndrome Diseases 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 3
- 206010034674 peritonitis Diseases 0.000 claims description 3
- 208000028591 pheochromocytoma Diseases 0.000 claims description 3
- 208000024724 pineal body neoplasm Diseases 0.000 claims description 3
- 201000004123 pineal gland cancer Diseases 0.000 claims description 3
- 208000037244 polycythemia vera Diseases 0.000 claims description 3
- 208000005987 polymyositis Diseases 0.000 claims description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 3
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 208000017443 reproductive system disease Diseases 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 230000033764 rhythmic process Effects 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 3
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- 201000003708 skin melanoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 201000010965 sweat gland carcinoma Diseases 0.000 claims description 3
- 206010042863 synovial sarcoma Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000005665 thrombophilia Diseases 0.000 claims description 3
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 claims description 3
- 230000001052 transient effect Effects 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000017997 tumor of parathyroid gland Diseases 0.000 claims description 3
- 241001529453 unidentified herpesvirus Species 0.000 claims description 3
- 230000002485 urinary effect Effects 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 1
- 102100040557 Osteopontin Human genes 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 130
- 238000011282 treatment Methods 0.000 abstract description 55
- 239000000203 mixture Substances 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 28
- 102000009410 Chemokine receptor Human genes 0.000 abstract description 7
- 108050000299 Chemokine receptor Proteins 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 229940126214 compound 3 Drugs 0.000 description 47
- 241000700159 Rattus Species 0.000 description 39
- 239000003981 vehicle Substances 0.000 description 37
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 32
- 210000000416 exudates and transudate Anatomy 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 210000000265 leukocyte Anatomy 0.000 description 30
- 229940125782 compound 2 Drugs 0.000 description 29
- 208000037329 crystal arthropathy Diseases 0.000 description 23
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 22
- 229940125904 compound 1 Drugs 0.000 description 21
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 20
- QZECRCLSIGFCIO-RISCZKNCSA-N n-[2-[(2,3-difluorophenyl)methylsulfanyl]-6-[(2r,3s)-3,4-dihydroxybutan-2-yl]oxypyrimidin-4-yl]azetidine-1-sulfonamide Chemical compound N=1C(SCC=2C(=C(F)C=CC=2)F)=NC(O[C@H](C)[C@@H](O)CO)=CC=1NS(=O)(=O)N1CCC1 QZECRCLSIGFCIO-RISCZKNCSA-N 0.000 description 20
- 238000010254 subcutaneous injection Methods 0.000 description 20
- 239000007929 subcutaneous injection Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- 238000004820 blood count Methods 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 230000001154 acute effect Effects 0.000 description 14
- 230000035605 chemotaxis Effects 0.000 description 13
- 229940096397 interleukin-8 Drugs 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 229940124530 sulfonamide Drugs 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000008021 deposition Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 230000002195 synergetic effect Effects 0.000 description 11
- 208000036487 Arthropathies Diseases 0.000 description 10
- 102000015696 Interleukins Human genes 0.000 description 10
- 108010063738 Interleukins Proteins 0.000 description 10
- 208000012659 Joint disease Diseases 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 206010018634 Gouty Arthritis Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 8
- 238000011321 prophylaxis Methods 0.000 description 8
- 229940116269 uric acid Drugs 0.000 description 8
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 7
- 108050006947 CXC Chemokine Proteins 0.000 description 7
- 102000019388 CXC chemokine Human genes 0.000 description 7
- 206010012735 Diarrhoea Diseases 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 238000009825 accumulation Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 108010092464 Urate Oxidase Proteins 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- STIUWSWFXIBBKI-UHFFFAOYSA-N azetidine-1-sulfonamide Chemical compound NS(=O)(=O)N1CCC1 STIUWSWFXIBBKI-UHFFFAOYSA-N 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- 125000006247 phenyl propyl amino group Chemical group [H]N(*)C([H])([H])C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- RGBVWCQARBEPPW-UHFFFAOYSA-N cyclobut-3-ene-1,2-dione Chemical compound O=C1C=CC1=O RGBVWCQARBEPPW-UHFFFAOYSA-N 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 125000006308 propyl amino group Chemical group 0.000 description 5
- 230000001185 psoriatic effect Effects 0.000 description 5
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002975 chemoattractant Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 229940002157 colcrys Drugs 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 3
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 3
- 101710082501 C-X-C chemokine receptor type 1 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 3
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 3
- 229940043256 calcium pyrophosphate Drugs 0.000 description 3
- 229960001838 canakinumab Drugs 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000003399 chemotactic effect Effects 0.000 description 3
- 208000002849 chondrocalcinosis Diseases 0.000 description 3
- 229940084627 colchicine 0.5 mg Drugs 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- UCUGUQPGZNAZKD-UHFFFAOYSA-M sodium;6,8-dioxo-7,9-dihydro-3h-purin-2-olate;hydrate Chemical compound O.[Na+].N1C(=O)NC(=O)C2=C1NC(=O)[N-]2 UCUGUQPGZNAZKD-UHFFFAOYSA-M 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 2
- ASUMVAPLXCRBMA-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(2,3-dihydro-1,4-benzoxazin-4-yl)methanone Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2OCC1 ASUMVAPLXCRBMA-UHFFFAOYSA-N 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 2
- YYBOLPLTQDKXPM-UHFFFAOYSA-N 2-[3-(4-cyanonaphthalen-1-yl)pyridin-4-yl]sulfanyl-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)SC1=CC=NC=C1C1=CC=C(C#N)C2=CC=CC=C12 YYBOLPLTQDKXPM-UHFFFAOYSA-N 0.000 description 2
- RXIUEIPPLAFSDF-CYBMUJFWSA-N 2-hydroxy-n,n-dimethyl-3-[[2-[[(1r)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobuten-1-yl]amino]benzamide Chemical compound N([C@H](CC)C=1OC(C)=CC=1)C(C(C1=O)=O)=C1NC1=CC=CC(C(=O)N(C)C)=C1O RXIUEIPPLAFSDF-CYBMUJFWSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710082514 C-X-C chemokine receptor type 3 Proteins 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 description 2
- 108010034143 Inflammasomes Proteins 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000002791 Interleukin-8B Receptors Human genes 0.000 description 2
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 108020002496 Lysophospholipase Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 102000004264 Osteopontin Human genes 0.000 description 2
- 206010034464 Periarthritis Diseases 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 229920000153 Povidone-iodine Polymers 0.000 description 2
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 229940083914 URAT1 inhibitor Drugs 0.000 description 2
- 229940116731 Uricosuric agent Drugs 0.000 description 2
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical group OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 229940001007 aluminium phosphate Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229960004272 bucillamine Drugs 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 239000002820 chemotaxin Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 229960005101 febuxostat Drugs 0.000 description 2
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940076144 interleukin-10 Drugs 0.000 description 2
- 102000010681 interleukin-8 receptors Human genes 0.000 description 2
- 108010038415 interleukin-8 receptors Proteins 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 229960003838 lesinurad Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 2
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000011242 neutrophil chemotaxis Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 208000007578 phototoxic dermatitis Diseases 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229960001621 povidone-iodine Drugs 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000013309 psoriasis mouse model Methods 0.000 description 2
- WJJBIYLGJUVNJX-UHFFFAOYSA-N pyrimidine-2-sulfonamide Chemical class NS(=O)(=O)C1=NC=CC=N1 WJJBIYLGJUVNJX-UHFFFAOYSA-N 0.000 description 2
- 229960000424 rasburicase Drugs 0.000 description 2
- 108010084837 rasburicase Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000011125 single therapy Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960003329 sulfinpyrazone Drugs 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 210000005222 synovial tissue Anatomy 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 239000003383 uricosuric agent Substances 0.000 description 2
- 229950008988 verinurad Drugs 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 2
- 229940032415 zurampic Drugs 0.000 description 2
- YQYFEGTYCUQBEI-UHFFFAOYSA-N 1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea Chemical compound C1=CC(Cl)=C(S(=O)(=O)N2CCNCC2)C(O)=C1NC(=O)NC1=CC=CC(F)=C1Cl YQYFEGTYCUQBEI-UHFFFAOYSA-N 0.000 description 1
- OPCMVVKRCLOEDQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(methylamino)pentan-1-one Chemical compound ClC1=CC=C(C=C1)C(C(CCC)NC)=O OPCMVVKRCLOEDQ-UHFFFAOYSA-N 0.000 description 1
- NGYNBSHYFOFVLS-LBPRGKRZSA-N 1-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)[C@@H]2CNCCC2)=C1O NGYNBSHYFOFVLS-LBPRGKRZSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- BJBCSGQLZQGGIQ-QGZVFWFLSA-N 2-acetamidoethyl (2r)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetate Chemical compound O([C@@H](C(=O)OCCNC(=O)C)C=1C=CC(Cl)=CC=1)C1=CC=CC(C(F)(F)F)=C1 BJBCSGQLZQGGIQ-QGZVFWFLSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UBAYZMJYXBTDBB-UHFFFAOYSA-N 2-hydroxy-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1O UBAYZMJYXBTDBB-UHFFFAOYSA-N 0.000 description 1
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 1
- SXZGCYPEALSLFY-UHFFFAOYSA-N 2-pyridin-4-ylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=NC=C1 SXZGCYPEALSLFY-UHFFFAOYSA-N 0.000 description 1
- AVSGFRVSZZIUNB-UHFFFAOYSA-N 3-methylazetidine-1-sulfonamide Chemical compound CC1CN(S(N)(=O)=O)C1 AVSGFRVSZZIUNB-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- SRHSMXLXWORYJK-SSDOTTSWSA-N 5-[(2,3-difluorophenyl)methylsulfanyl]-7-[[(2r)-1-hydroxypropan-2-yl]amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound N=1C=2NC(=O)SC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(F)=C1F SRHSMXLXWORYJK-SSDOTTSWSA-N 0.000 description 1
- KHTUORKUWBDRBX-SSDOTTSWSA-N 5-[(3-chloro-2-fluorophenyl)methylsulfanyl]-7-[[(2r)-1-hydroxypropan-2-yl]amino]-3h-[1,3]thiazolo[4,5-d]pyrimidin-2-one Chemical compound N=1C=2NC(=O)SC=2C(N[C@@H](CO)C)=NC=1SCC1=CC=CC(Cl)=C1F KHTUORKUWBDRBX-SSDOTTSWSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710082516 C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 108091008928 CXC chemokine receptors Proteins 0.000 description 1
- 102000054900 CXCR Receptors Human genes 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010052273 Dystrophic calcification Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 206010023848 Laryngeal pain Diseases 0.000 description 1
- 241000724182 Macron Species 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000023137 Myotoxicity Diseases 0.000 description 1
- 102000012064 NLR Proteins Human genes 0.000 description 1
- 108091005686 NOD-like receptors Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010062284 Neuromuscular toxicity Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- DDLPYOCJHQSVSZ-SSDOTTSWSA-N [4-[(2r)-1-(methanesulfonamido)-1-oxopropan-2-yl]phenyl] trifluoromethanesulfonate Chemical compound CS(=O)(=O)NC(=O)[C@H](C)C1=CC=C(OS(=O)(=O)C(F)(F)F)C=C1 DDLPYOCJHQSVSZ-SSDOTTSWSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229950001019 arhalofenate Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 230000007214 atherothrombosis Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 231100001015 blood dyscrasias Toxicity 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940046362 colchicine 1 mg Drugs 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000003340 combinatorial analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229950003518 danirixin Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229950006357 elubrixin Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000001255 hallux Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000013029 homogenous suspension Substances 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 229950010517 ladarixin Drugs 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- IMNDHOCGZLYMRO-UHFFFAOYSA-N n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=CC=C1 IMNDHOCGZLYMRO-UHFFFAOYSA-N 0.000 description 1
- 229950003726 navarixin Drugs 0.000 description 1
- 231100000166 neuromuscular toxicity Toxicity 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000000207 pro-atherogenic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002947 procoagulating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- KQDRVXQXKZXMHP-LLVKDONJSA-N reparixin Chemical compound CC(C)CC1=CC=C([C@@H](C)C(=O)NS(C)(=O)=O)C=C1 KQDRVXQXKZXMHP-LLVKDONJSA-N 0.000 description 1
- 229950005650 reparixin Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/702,693 US20180221312A1 (en) | 2016-03-11 | 2017-09-12 | Cxcr-2 inhibitors for treating disorders |
| US15/702,693 | 2017-09-12 | ||
| PCT/US2018/050656 WO2019055509A1 (en) | 2017-09-12 | 2018-09-12 | INHIBITORS OF CXCR-2 FOR THE TREATMENT OF DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3075305A1 true CA3075305A1 (en) | 2019-03-21 |
Family
ID=65723077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3075305A Pending CA3075305A1 (en) | 2017-09-12 | 2018-09-12 | Cxcr-2 inhibitors for treating disorders |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3681861A4 (de) |
| JP (1) | JP2020533332A (de) |
| CN (1) | CN111356675A (de) |
| AR (1) | AR112801A1 (de) |
| AU (1) | AU2018334152A1 (de) |
| BR (1) | BR112020004697A2 (de) |
| CA (1) | CA3075305A1 (de) |
| CO (1) | CO2020003061A2 (de) |
| MX (2) | MX2020002754A (de) |
| TW (1) | TW201919599A (de) |
| WO (1) | WO2019055509A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113893252A (zh) | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| US20220404373A1 (en) * | 2019-09-25 | 2022-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and treating uveitis |
| WO2021089715A1 (en) * | 2019-11-06 | 2021-05-14 | Murray And Poole Enterprises, Ltd. | Use of colchicine in the treatment and prevention of lung cancer |
| MX2022005795A (es) * | 2019-11-13 | 2022-06-08 | Rapt Therapeutics Inc | Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas. |
| IL298748A (en) * | 2020-06-05 | 2023-02-01 | Aristea Therapeutics Inc | Use of a combination of colchicine and a CXCR-2 inhibitor for the treatment or prevention of hereditary Mediterranean fever (FMF) and its outbreaks |
| TWI774059B (zh) * | 2020-09-14 | 2022-08-11 | 國立陽明大學 | Ｃｘｃｌ５中和抗體用於製備預防或治療周邊動脈阻塞疾病的藥物的用途 |
| WO2022060736A1 (en) * | 2020-09-15 | 2022-03-24 | Aristea Therapeutics, Inc. | Compositions and methods for the treatment of palmoplantar pustulosis |
| CN116507346A (zh) * | 2020-09-24 | 2023-07-28 | 广州辑因医疗科技有限公司 | 化合物用于提高人造血干细胞移植效率的用途 |
| CN115385865B (zh) * | 2022-06-29 | 2023-06-16 | 深圳大学 | 一种具有cxcr2抑制活性的小分子抑制剂及其制备方法与应用 |
| CN117503740A (zh) * | 2023-11-09 | 2024-02-06 | 复旦大学 | 一种bach1抑制剂及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2388756C2 (ru) * | 2004-01-30 | 2010-05-10 | Шеринг Корпорейшн | Кристаллические полиморфные формы лиганда схс-хемокинового рецептора |
| US8298533B2 (en) * | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| CN103781781B (zh) * | 2011-07-12 | 2015-08-26 | 阿斯利康(瑞典)有限公司 | 作为趋化因子受体调节剂的n-(6-((2r,3s)-3,4-二羟基丁-2-基氧基)-2-(4-氟苄基硫基)嘧啶-4-基)-3-甲基氮杂环丁烷-1-磺酰胺 |
| CN113893252A (zh) * | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
-
2018
- 2018-09-12 MX MX2020002754A patent/MX2020002754A/es unknown
- 2018-09-12 BR BR112020004697-3A patent/BR112020004697A2/pt unknown
- 2018-09-12 EP EP18856459.5A patent/EP3681861A4/de not_active Withdrawn
- 2018-09-12 TW TW107132083A patent/TW201919599A/zh unknown
- 2018-09-12 CN CN201880073230.7A patent/CN111356675A/zh active Pending
- 2018-09-12 WO PCT/US2018/050656 patent/WO2019055509A1/en unknown
- 2018-09-12 JP JP2020514219A patent/JP2020533332A/ja active Pending
- 2018-09-12 CA CA3075305A patent/CA3075305A1/en active Pending
- 2018-09-12 AU AU2018334152A patent/AU2018334152A1/en not_active Abandoned
- 2018-09-12 AR ARP180102592A patent/AR112801A1/es unknown
-
2020
- 2020-03-11 MX MX2022014868A patent/MX2022014868A/es unknown
- 2020-03-16 CO CONC2020/0003061A patent/CO2020003061A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022014868A (es) | 2022-12-15 |
| EP3681861A1 (de) | 2020-07-22 |
| CN111356675A (zh) | 2020-06-30 |
| BR112020004697A2 (pt) | 2020-10-27 |
| EP3681861A4 (de) | 2021-06-09 |
| JP2020533332A (ja) | 2020-11-19 |
| WO2019055509A1 (en) | 2019-03-21 |
| TW201919599A (zh) | 2019-06-01 |
| AU2018334152A1 (en) | 2020-04-23 |
| MX2020002754A (es) | 2020-07-20 |
| AR112801A1 (es) | 2019-12-11 |
| CO2020003061A2 (es) | 2020-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3075305A1 (en) | Cxcr-2 inhibitors for treating disorders | |
| US20200281878A1 (en) | Cxcr-2 inhibitors for treating disorders | |
| US7119120B2 (en) | Phosphate transport inhibitors | |
| US6232315B1 (en) | Method for treating inflammatory diseases by administering a thrombin inhibitor | |
| JP6159484B2 (ja) | グレリンｏ−アシルトランスフェラーゼ阻害剤 | |
| JP7126014B2 (ja) | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 | |
| WO2020150552A2 (en) | Methods of treating cartilage disorders through inhibition of clk and dyrk | |
| WO2010071866A2 (en) | Combination therapy for arthritis with tranilast | |
| JP2002529503A (ja) | ニトロソ化及びニトロシル化ｈ２リセプターアンタゴニスト化合物及び組成物並びにその利用方法 | |
| WO2006086456A2 (en) | Combination of organic compounds | |
| JP2021512935A (ja) | 疼痛を処置する方法 | |
| CA2788437A1 (en) | Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors | |
| CN104066324A (zh) | 治疗痛风急性发作的方法 | |
| KR20220110261A (ko) | 코로나바이러스의 치료 방법 | |
| US11345696B2 (en) | Compounds and methods of treating or ameliorating an IL-1R-mediated disease or disorder using same | |
| US20130338372A1 (en) | Substituted Imidazoline Compounds | |
| CA1330446C (en) | Phenolic thioalkylamides as inhibitors of 5-lipoxygenase | |
| JP6401265B2 (ja) | Ｎ−（４−クロロ−２−ヒドロキシ−３−（（３ｓ）−３−ピペリジニルスルホニル）フェニル−ｎ’−（３−フルオロ−２−メチルフェニル）尿素の臭化水素酸塩 | |
| US20140127295A1 (en) | Compositions, process of preparation of said compositions and method of treating inflammatory diseases | |
| KR20210027408A (ko) | 콜히친 유도체의 방법 및 용도 | |
| WO2006095822A1 (ja) | スルホンアミド化合物およびその医薬 | |
| JP2018503691A (ja) | 尿酸性または痛風性疾患の予防または治療 | |
| ERION | QUN DANG*, PAUL D. VAN POELJE AND |